Recent News

PECA Labs' exGraft Helps Save Lives -- Case Report

Friday, October 12

Just a few weeks ago, an infant boy’s life was saved by a surgeon using the PECA Labs exGraft. Between the mundanity of regulatory compliance and supply-chain management, it could be easy to lose sight of the ultimate impact of our work.

Read More

Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant for Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease

Tuesday, October 02

Pittsburgh, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a multiyear grant expected to total $16.6 million to support the Phase 2 SHINE study of Elayta™ (CT1812).

Read More

Cognition Therapeutics Presents Additional Elayta™ Clinical Results during Alzheimer's Association International Conference (AAIC) Symposium Session

Monday, July 23

Pittsburgh, July 23, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurodegenerative disorders, today announced that co-founder and Chief Science Officer Susan Catalano, Ph.D. presented additional findings supporting the unique synaptorestorative mechanism of action of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease, at the Alzheimer's Association International Conference (AAIC) in Chicago. Dr. Catalano was invited by the Association to present these results as part of the July 23rd Symposium Session: Translational Research In Reality - What Are The Criteria From Concept To Clinic?

Read More

Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer's Disease

Monday, June 18

Pittsburgh, June 18, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today announced that patient dosing has begun in the SPARC (Synaptic Protection for Alzheimer’s Restoration of Cognition) study of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease.

Read More

Wombat Exit Marks BlueTree's Biggest Return to Date

Monday, June 11

Being an early investor paid off big time for BlueTree Allied Angels.

More specifically, the Wexford-based angel network notched a 12 times return on the $266,500 it invested during a three-year period in Wombat Security Technologies.


Read More

Peptilogics Receives Qualified Infectious Disease Product Designation from FDA for Lead Compound PLG0206 as a Treatment for Prosthetic Joint Infection

Thursday, June 07

PITTSBURGH, Pa. & SAN JOSE, Calif.--(BUSINESS WIRE)--Peptilogics, a development stage company utilizing its innovative peptide platform to treat multidrug-resistant bacterial infections, today announced that its lead compound PLG0206 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for the treatment of prosthetic joint infections (PJI).

Read More

Cognition Therapeutics Initiates NIA-Funded SNAP Study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer's Disease

Wednesday, June 06

Pittsburgh, June 05, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the first patient has been dosed in the SNAP (AβO Displacement from Synapses on Neurons in Alzheimer’s Patients) Study of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease (AD). The SNAP Study is enrolling patients at the University of Pennsylvania School of Medicine under the direction of Yvette I. Sheline, M.D., the McLure Professor of Psychiatry and Behavioral Research.

Read More

Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action

Friday, May 25

PITTSBURGH, May 22, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced the receipt of two multi-year grants from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) totaling $6.6 million. These awards will fund two clinical studies of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease, which are primarily designed to probe Elayta’s unique synaptoprotective mechanism of action.

Read More

VC-Backed Complexa Recruits Salva as CEO and President

Friday, May 18

BERWYN, Pa.–(BUSINESS WIRE)–Complexa Inc., a clinical stage biopharmaceutical company, today announced the appointment of Francisco D. Salva as the company’s new Chief Executive Officer and President, effective immediately. Mr. Salva has been appointed to build on the company’s progress to date by further advancing the Phase 2 clinical development of its lead compound CXA-10 in two orphan indications, pulmonary arterial hypertension and focal segmental glomerulosclerosis. He will also focus on the development of the next-generation of nitrated fatty acid compounds to support the growth of the company.

Read More